Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Lucentis in Advanced Macular Degeneration
Authors not listed
Steven R. Sanislo · 2009
Abstract
Patients with low vision (visual acuity 20/400 or worse) were excluded from the large Phase III ranibizumab clinical trials. It is not known if treatment with ranibizumab results in improved visual function in such patients.Since ranibizumab has been shown to be the most effective therapy for exudative macular degeneration we propose to treat all patients in this study with monthly ranibizumab intravitreal injections.
Patients will be assigned to one of two groups by the flip of a coin. Group #1 for "heads" and Group #2 for "tails".
Group #1 patients will be treated for 3 monthly injections of 0.5 mg of ranibizumab and then as needed therapy.
Group #2 will be treated with 6 monthly injections of 0.5 mg of ranibizumab and then as needed therapy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2009). Lucentis in Advanced Macular Degeneration. <em>Steven R. Sanislo</em>. https://clinicaltrials.gov/study/NCT00896779
Vancouver
Anonymous. Lucentis in Advanced Macular Degeneration. Steven R. Sanislo. 2009.
BibTeX
@misc{anon2009Lucent,
title = {Lucentis in Advanced Macular Degeneration},
author = {Anonymous},
journal = {Steven R. Sanislo},
year = {2009},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Control Delivery Systems 2001
Open access · US-GOV
A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
Rishi Singh 2012
Open access · US-GOV
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
Retina Associates of Florida, P.A. 2010
Open access · US-GOV
REVOLUTIONARY: REtinal Vein OccLUsion Treatment With Scatter Laser Guided by Ultra Widefield angIOgraphy in combiNAtion With Ranibizumab Study Phase II
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH 2010
Open access · US-GOV
Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)
Michel Giunta 2019
Open access · US-GOV
Exploratory and Descriptive Study Evaluating the Efficacy of Aflibercept in Bimonthly Injections Versus the ''Treat and Extend'' Dosing Regimen
Oklahoma State University Center for Health Sciences 2007
Open access · US-GOV